Co-targeting of MEK and AKT signaling showed some durable response in a phase I study [55], and most recently, a small trial showed some success combining an investigational MEK inhibitor with a CDK4/6 inhibitor in non-small cell lung cancer (NSCLC) (trial NCT number NCT02022982). Here, AKT1 is linked to non-small cell lung carcinoma.